BioLife Solutions (BLFS)
(Delayed Data from NSDQ)
$22.88 USD
+0.79 (3.58%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $22.87 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
BioLife Solutions, Inc. (BLFS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$24.67 | $30.00 | $15.00 | 11.68% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for BioLife Solutions, Inc. comes to $24.67. The forecasts range from a low of $15.00 to a high of $30.00. The average price target represents an increase of 11.68% from the last closing price of $22.09.
Analyst Price Targets (9 )
Broker Rating
BioLife Solutions, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, nine are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/17/2024 | Cowen & Co. | Steven Mah | Strong Buy | Strong Buy |
5/24/2024 | Maxim Group | Michael Okunewitch | Strong Buy | Strong Buy |
5/13/2024 | The Benchmark Company | Robert Wasserman | Hold | Strong Buy |
5/1/2024 | Stephens | Jacob Johnson | Strong Buy | Strong Buy |
4/18/2024 | Lake Street Capital Markets | Thomas Flaten | Strong Buy | Strong Buy |
3/1/2024 | Northland Capital Markets | Carl Byrnes | Strong Buy | Strong Buy |
11/10/2023 | Craig-Hallum | Matthew G Hewitt | Strong Buy | Strong Buy |
11/9/2023 | KeyBanc Capital Markets | Paul Knight | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 9 |
Average Target Price | $24.67 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 149 of 253 |
Current Quarter EPS Est: | -0.14 |